215 institutions reported holding HROW for 2026Q1, together 57% of the company, more than the 211 a quarter earlier. Institutions reporting a position: 215 (as of 2026Q1). Shares held by institutions: 21.4M, long US equity positions only, as reported on Form 13F. Reported value: $755M, at 2026-03-31 prices, not today's. Top 5 holders: 27%, of the whole company, between five filers.

HROWHarrow, Inc.

HealthcareUSD

$39.32

$29.0352 weeks$54.80

Who owns HROW

215 institutions reported holding HROW for 2026Q1, together 57% of the company, more than the 211 a quarter earlier.

215

Institutions reporting a position · as of 2026Q1 · up from 211 the quarter before

Shares held by institutions: 21.4M
Shares held by institutions · 57% of the company · long US equity positions only, as reported on Form 13F
Reported value: $755M
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 27%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 30
New positions: 38
Positions exited: 40
Added to: 62
Reduced: 72
Top 10 holdersof the company: 36%

Institutional ownership by quarter, 2018Q4 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	215	21.4M	$755M
2025Q4	211	22.2M	$1.09B
2025Q3	195	21.3M	$1.02B
2025Q2	159	21.1M	$643M
2025Q1	155	20.7M	$551M
2024Q4	164	20.8M	$699M
2024Q3	157	20.9M	$940M
2024Q2	108	19.0M	$397M
2024Q1	112	20.6M	$273M
2023Q4	112	22.8M	$256M
2023Q3	128	24.9M	$358M
2023Q2	112	23.0M	$438M
2023Q1	114	20.9M	$442M
2022Q4	94	17.9M	$264M
2022Q3	81	15.3M	$185M
2022Q2	88	16.2M	$147M

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
Opaleye Management Inc.	2.8M	7.6%	$100M
BlackRock Inc.	2.6M	6.9%	$90M
VANGUARD GROUP INC	2.0M	5.3%	$69M
Private Capital Management, LLC	1.6M	4.2%	$55M
Luxor Capital Group, LP	1.1M	3.0%	$39M
STATE STREET CORP	0.9M	2.3%	$30M
GEODE CAPITAL MANAGEMENT LLC	0.9M	2.3%	$30M
Marshall Wace LLP	0.6M	1.7%	$23M
DIMENSIONAL FUND ADVISORS LP	0.6M	1.6%	$20M
Ikarian Capital, LLC	0.5M	1.5%	$19M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Drug Manufacturers - Specialty & Generic

Ranks #26 of 28 by Smart Score

Compare peers

HCM+0.19%

HUTCHMED (China) Limited

PRGO-0.82%

Perrigo Company plc

PAHC+1.5%

Phibro Animal Health Corporation

XERS0.00%

Xeris Biopharma Holdings, Inc.

ANIP+0.68%

ANI Pharmaceuticals, Inc.

AMLX+2.6%

Amylyx Pharmaceuticals, Inc.